UBS reiterates Buy rating on Lifestance Health stock with $9 price target
PositiveFinancial Markets

UBS has reaffirmed its Buy rating on Lifestance Health stock, setting a price target of $9. This endorsement reflects confidence in Lifestance's growth potential and market position, making it an attractive option for investors looking for promising healthcare stocks.
— Curated by the World Pulse Now AI Editorial System